Upstream Bio, Inc. Common Stock UPB
Analyst Ratings
- Consensus
- Moderate Buy — 4 Buy · 2 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $29.67 (+974.9% upside)
Key Stats
- Today's Range
- $2.74 – $3.39
- 50-Day Range
- $2.74 – $7.70
- 52-Week Range
- $2.74 – $33.68
- Volume
- 1.84 million shs
- Average Volume
- 875K shs
- Market Cap
- $151.17 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.42%
- Days to Cover
- 1.00
About Upstream Bio, Inc. Common Stock
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
Related Stocks
Compare head-to-head: UPB vs LLY·UPB vs JNJ·UPB vs ABBV·UPB vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.